Predictive and prognostic markers in neuro-oncology

Journal of Neuropathology and Experimental Neurology

Volumn 66, Issue 12, 2007, Pages 1074-1081

  Van Den Bent, Martin J ^a   Kros, Johan M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

19q; 1p; Epidermal growth factor receptor; Epidermal growth factor receptor vIII mutant; MGMT; Predictive significance; Prognostic significance

Indexed keywords

CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; CANCER SURVIVAL; CHROMOSOME LOSS; CLINICAL TRIAL; GLIOBLASTOMA; HUMAN; NEUROLOGIC DISEASE; OLIGODENDROGLIOMA; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 19; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 37349051400     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e31815c39f1     Document Type: Review

References (60)

1. Scott CB, Nelson JS, Farnan NC, et al. Central pathology review in clinical trials for patients with malignant glioma. Cancer 1995;76:307-13
2. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52
3. van den Bent MJ, Afra D, De Witte O, et al. Long term results of EORTC study 22845: A randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult. Lancet 2005;366:985-90
4. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-21
5. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-91
6. Burger PC. What is an oligodendroglioma? Brain Pathol 2002;12:257-59
7. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90
8. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-61
9. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1; 19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-94
10. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-1104
11. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
12. van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-84
13. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 2006;42:2499-503
14. Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study. J Clin Oncol 2006;24:4746-53
15. Biemond-ter Stege E, Kros JM, de Bruin HG, et al. Treatment of low grade oligodendroglial tumors with PCV chemotherapy. Cancer 2005;103:802-809
16. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-38
17. McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 2005;104:1468-77
18. Walker C, du Plessis DG, Joyce KA, et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 2005;57:855-65
19. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45
20. Bauman GS, Ino Y, Yeki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys 2000;48:825-30
21. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized EORTC phase III trial. J Clin Oncol 2006;24:2715-22
22. Cairncross JG, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): An intergroup trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol 2006;24:2707-14
23. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
24. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev 2004;4:296-307
25. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group Study. J Clin Oncol 1998;16:3310-15
26. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-54
27. Tanaka S, Kobayashi I, Utsuki S, et al. O6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 2003;103:67-72
28. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003
29. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 2006;12:4738-46
30. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005;11:5167-74
31. Criniere E, Kaloshi G, Laigle-Donadey F, et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007;83:173-79
32. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-57
33. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: A marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740-43
34. Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006;24:4412-17
35. Möllemann M, Wolter M, Felsberg J, et al. Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2004;113:379-85
36. Eley GD, Reiter JL, Pandita A, et al. A chromosomal region 7p11.2 transcript map: Its development and application to the study of EGFR amplicons in glioblastoma. Neuro Oncol 2002;4:86-94
37. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-87
38. Frederick L, Wang XY, Eley G, et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-87
39. Nishikawa R, Ji X, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-31
40. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR amplification. Oncogene 1994;9:2313-20
41. Liu L, Backlund LM, Nilsson BR, et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 2005;83:917-26
42. Heimberger AB, Suki D, Yang D, et al. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005;3:38
43. Quan AL, Barnett GH, Lee SY, et al. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2005;63:695-703
44. Chakravarti A, Seiferheld W, Tu X, et al. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005;62:318-27
45. Dehais C, Laigle-Donadey F, Marie Y, et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 2006;107:1891-97
46. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63:700-7
47. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
48. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
49. Marie Y, Carpentier AF, Omuro AM, et al. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005;64:1444-45
50. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11:7841-50
51. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24
52. Learn CA, Hartzell TL, Wikstrand CJ, et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004;10:3216-24
53. Prados M, Chang S, Burton E, et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma (Abstract 394). Proc Am Soc Clin Oncol 2003;22:99
54. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas not on EIAEDs (Abstract 1502). Proc Am Soc Clin Oncol 2004;40:107
55. Vogelbaum MA, Peereboom D, Stevens GHJ, et al. Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: Results of a phase II study (Abstract A-59). Neuro Oncol 2004;6:384
56. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42
57. Lieberman FS, Cloughesy I, Malkin M, et al. Phase IYII study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy [abstract 421]. J Clin Oncol 2003;22:105
58. Cloughesy T, Yung A, Vrendenberg J, et al. Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome (Abstract #1507). Proc Am Soc Clin Oncol 2005;41:115
59. Haas-Kogan DA, Prados MD, Lamborn KR, et al. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005;4:1369-72
60. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006;12:3935-41